Please check your internet connection and try again.
# Arsil
## Overview
Arsil is a brand name for a product containing Arsenic Trioxide. Arsenic trioxide is a chemotherapeutic agent used in the treatment of certain hematologic malignancies.
## Primary Indications
* Acute Promyelocytic Leukemia (APL) that is refractory to retinoid and anthracycline chemotherapy.
## Adult Dosing
* For induction therapy: 0.15 mg/kg intravenously once daily. Treatment is typically given on days 1-4 and 8-11 of each cycle, for up to 4 cycles.
* For consolidation therapy: 0.15 mg/kg intravenously twice weekly (e.g., Monday and Thursday) for 3 weeks. Treatment is typically given for 2 cycles.
**Note:** Dosing and treatment schedules may vary based on specific institutional protocols and patient response.
## Pediatric Dosing
Dosing in pediatric patients is not well-established and should be determined by a pediatric oncologist. Limited data suggests doses similar to adults (0.15 mg/kg/day).
## Dose Adjustments
* **Hepatotoxicity:** Dose interruption or reduction may be necessary.
* **Leukocytosis:** If white blood cell (WBC) count increases significantly, consider initiating all-trans retinoic acid (ATRA) therapy. Dose adjustments for arsenic trioxide may be needed based on ATRA use and WBC count.
* **QTc Prolongation:** Dose interruption may be necessary.
## Contraindications
* Hypersensitivity to arsenic trioxide.
## Adverse Effects
* **Common:** Leukocytosis, febrile neutropenia, hyperglycemia, hypokalemia, hypomagnesemia, QTc prolongation, nausea, vomiting, diarrhea, abdominal pain, fatigue, rash, edema, muscle cramps.
* **Serious:** Differentiation Syndrome (also known as Retinoic Acid Syndrome), cardiac arrhythmias, liver injury, peripheral neuropathy, pancreatitis, rhabdomyolysis.
## Key Drug Interactions
* **Drugs known to prolong QTc interval:** Concurrent use with arsenic trioxide increases the risk of QTc prolongation and torsades de pointes. Examples include antiarrhythmics (Class IA and III), antipsychotics, and fluoroquinolones.
* **CYP450 substrates:** Arsenic trioxide can inhibit certain CYP enzymes, potentially increasing concentrations of co-administered drugs. Monitor for toxicity.
* **Diuretics:** May exacerbate electrolyte disturbances (hypokalemia, hypomagnesemia) which can increase the risk of QTc prolongation.
## Monitoring
* **Hematologic:** Complete blood count (CBC) with differential, including WBC count, to monitor for leukocytosis and response.
* **Electrolytes:** Potassium, magnesium, and phosphate levels regularly, especially with diuretic use.
* **Cardiac:** Electrocardiogram (ECG) to monitor QTc interval, especially at baseline, after initiating therapy, and periodically throughout treatment.
* **Hepatic:** Liver function tests (LFTs).
* **Renal:** Renal function tests.
* **Clinical signs and symptoms:** Monitor for signs of Differentiation Syndrome.
## Clinical Pearls
* Differentiation Syndrome is a potentially life-threatening condition characterized by fever, dyspnea, pulmonary infiltrates, pleural or pericardial effusions, and edema. It requires prompt recognition and management, often with corticosteroids and ATRA.
* Electrolyte imbalances are common and can increase the risk of cardiac arrhythmias. Aggressive correction of hypokalemia, hypomagnesemia, and hypophosphatemia is crucial.
* Regular ECG monitoring is essential due to the risk of QTc prolongation.
***
**Disclaimer:** This information is intended for healthcare professionals and does not substitute for comprehensive drug information resources. Always consult the most current prescribing information and institutional guidelines before making clinical decisions.
